Evidence map›Paper›PMID 38612495›Full record

ArticleInternational journal of molecular sciences2024

Discrimination of Etiologically Different Cholestasis by Modeling Proteomics Datasets.

Laura Guerrero, Jorge Vindel-Alfageme, Loreto Hierro, Luiz Stark, David Vicent, Carlos Óscar S Sorzano, Fernando J Corrales

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Laura GuerreroCentro Nacional de Biotecnología (CNB-CSIC), c/Darwin, 3, 28049 Madrid, Spain.ORCID 0000-0002-1842-8449
Jorge Vindel-AlfagemeCentro Nacional de Biotecnología (CNB-CSIC), c/Darwin, 3, 28049 Madrid, Spain.
Loreto HierroIdiPAZ, Instituto de Investigación Sanitaria (Health Research Institute), Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain.
Luiz StarkIdiPAZ, Instituto de Investigación Sanitaria (Health Research Institute), Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain.ORCID 0000-0001-9391-1409
David VicentIdiPAZ, Instituto de Investigación Sanitaria (Health Research Institute), Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain.ORCID 0000-0002-6663-0350
Carlos Óscar S SorzanoCentro Nacional de Biotecnología (CNB-CSIC), c/Darwin, 3, 28049 Madrid, Spain.ORCID 0000-0002-9473-283X
Fernando J CorralesCentro Nacional de Biotecnología (CNB-CSIC), c/Darwin, 3, 28049 Madrid, Spain.ORCID 0000-0002-0231-5159

Funding

PHARMACOLOGY OF DRUG ABUSET32DA007232 · NIDA · UNIVERSITY OF ROCHESTER · PI BIDLACK, JEAN M · 1985 to 2011
$2.1M
NEUROBEHAVIORAL MECHANISMS OF DRUG ADDICTIONR01DA003817 · NIDA · ALBANY MEDICAL COLLEGE · PI GLICK, STANLEY D · 1985 to 2001
$370k
Comunidad de Madrid 2022/BMD-7232Comunidad de Madrid B2017/BMD-3817Ministerio de Ciencia e Innovación PID2021-127496NB-100Spanish National Research Council 202020E079Spanish National Research Council 202020E108
6 · The paper itself

Abstract

Cholestasis is characterized by disrupted bile flow from the liver to the small intestine. Although etiologically different cholestasis displays similar symptoms, diverse factors can contribute to the progression of the disease and determine the appropriate therapeutic option. Therefore, stratifying cholestatic patients is essential for the development of tailor-made treatment strategies. Here, we have analyzed the liver proteome from cholestatic patients of different etiology. In total, 7161 proteins were identified and quantified, of which 263 were differentially expressed between control and cholestasis groups. These differential proteins point to deregulated cellular processes that explain part of the molecular framework of cholestasis progression. However, the clustering of different cholestasis types was limited. Therefore, a machine learning pipeline was designed to identify a panel of 20 differential proteins that segregate different cholestasis groups with high accuracy and sensitivity. In summary, proteomics combined with machine learning algorithms provides valuable insights into the molecular mechanisms of cholestasis progression and a panel of proteins to discriminate across different types of cholestasis. This strategy may prove useful in developing precision medicine approaches for patient care.

Indexed as

CholestasisProteomicsAlgorithmsCluster AnalysisHumansLivercholestasislivermachine learningquantitative proteomics

Identifiers

PMID38612495
PMCPMC11011353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.